14.11.2018 • News

Saudi Aramco IPO on track for 2021?

Saudi Aramco IPO on track for 2021? © 2018 Saudi Arabian Oil Co.
Saudi Aramco IPO on track for 2021? © 2018 Saudi Arabian Oil Co.

Saudi Aramco continues to dangle possible dates for its several times delayed initial public offering in front of the market. At the ADIPEC oil forum in Abu Dhabi last weekend,  the company’s CEO Amin Nasser said the listing is still on track, but not before 2021.

Repeating earlier statements, Nasser told the network CNBC that the Saudi government will decide “when the time is right,” but added that both crown prince Mohammed bin Salman and energy minister Khalid al-Falih are targeting an ipo within three years.

The crown prince, who has persistently pushed for the state-controlled firm to go public,  has suggested Aramco could be worth in excess of $2 trillion. Many financial market observers, however, believe this target is unrealistically high.

Analysts have commented that in seeking a listing the Saudis may have overlooked the amount of work this necessitates. While volatility on international stock exchanges could be an extenuating factor, the movement of oil prices is also deemed to be of primary interest. Until recently, prices have been moving mainly south.

Plans for Aramco to take a majority stake in the country’s leading chemical producer SABIC -which are proceeding apace- could cause further delays, as Nasser acknowledged in Abu Dhabi. The government’s plan is said to be to shift some sales of crude oil to petrochemicals and diversify more downstream.

Through Saudi Arabia’s Public Investment Fund (PIF), the oil group is picking up the state’s 70% stake in the Saudi chemicals giant  – the remaining shares are listed on the Saudi Stock Exchange.

Reports from the meeting quoted Nasser as saying – in response to questions – that he didn’t think the “unexplained death” of journalist Jamal Khashoggi in Turkey had tarnished Saudi Arabia’s image.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.